3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
5
Lung Neoplasms
4
Glioblastoma
3
Urinary Bladder Neoplasms
2
Glioma
2
Brain Neoplasms
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Tuberculosis, Pulmonary
1
Thyroid Nodule
1
Stomach Neoplasms
1
Solitary Pulmonary Nodule
1
Pulmonary Fibrosis
1
Pulmonary Embolism
1
Pulmonary Disease, Chronic Obstructive
1
Pulmonary Arterial Hypertension
1
Pleural Neoplasms
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Pulmonary Nodules
1
Mesothelioma
1
Lung Injury
1
Lung Diseases, Interstitial
1
Lung Diseases
1
Lung Abscess
1
Esophageal Neoplasms
1
Emphysema
1
Disease
1
Cystic Fibrosis
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
40
Cisplatin
25
Fluorouracil
24
Paclitaxel
21
Oxaliplatin
16
Capecitabine
12
Leucovorin
10
Irinotecan
10
Docetaxel
10
Gemcitabine
8
Carboplatin
7
atezolizumab
6
Nivolumab
6
Bevacizumab
6
Trastuzumab
5
Ramucirumab
5
Radiotherapy
5
spartalizumab
4
Albumin-Bound Paclitaxel
4
zanidatamab
3
tisotumab vedotin
3
patritumab deruxtecan
3
lenvatinib
3
fludarabine
3
durvalumab
3
Radiation
3
Drug Therapy
3
Cyclophosphamide
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Neoplasms
×
Drug Delivery Systems
×
Clear all
NCT05899985
2026-04-06
MAGMAP
Ferronova Pty Ltd
Phase NA
Active not recruiting
60 enrolled